RCUS Q4 2022 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$34M-90.5% YoY

Gross Profit

$34M100.0% margin

Operating Income

-$74M-221.2% margin

Net Income

-$67M-200.4% margin

EPS (Diluted)

$-0.92

QoQ Revenue Growth

+2.0%

Cash Flow

Operating Cash Flow

-$70M

Free Cash Flow

-$70M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$688M

Stockholders' Equity

$657M

Cash & Equivalents

$206M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$34M	$354M	-90.5%
Gross Profit	$34M	$354M	-90.5%
Operating Income	-$74M	$281M	-126.5%
Net Income	-$67M	$279M	-124.1%

Revenue Segments

License and Development Services Revenue

$26M76%

Other Collaboration Revenue

$8M24%